[Should acute myeloblastic leukemias be treated in elderly patients?].
D000367:Age Factors; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004338:Drug Combinations; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012008:Recurrence; D012075:Remission, Spontaneous
D000970:Antineoplastic Agents; D004338:Drug Combinations; D003561:Cytarabine; D003630:Daunorubicin
Faut-il traiter les leucémies aiguës myéloblastiques du sujet ägé.